Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Intranasal S. pyogenes vaccine

January 18, 2024 12:57 AM UTC

An adjuvanted, intranasal, liposomal peptide vaccine delivering a cryptic Streptococcus pyogenes antigen could help prevent infection by activating Th17 cells while avoiding autoimmune molecular mimicry.

The vaccine comprised liposomes containing a cryptic peptide from the C3-repeat region of the S. pyogenes M protein, and was adjuvanted by a TLR4 ligand and diptheria toxoid. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Griffith University

BCIQ Target Profiles

Toll-like receptor 4 (TLR4)